PRESS-RELEASE filed Jun 29, 2026 at 06:00 ET
Zymeworks Inc. (ZYME) announced an agreement to acquire Theravance Biopharma (TBPH) for $17.00 per share, or approximately $929 million in total cash consideration. The acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized LAMA for COPD maintenance treatment, which generated ~$60 million in annualized cash flow. The deal is financed via a $350 million non-recourse note from OMERS Life Sciences, $219 million of Zymeworks' cash, and Theravance's ~$360 million expected net cash, with an expected $100 million TRELEGY milestone in Q1 2027 reducing net investment. The transaction is expected to be accretive to earnings and cash flow upon closing in H2 2026.